18 June 2013 - 18 June 2013 - US MannKind Corp (NASDAQ:MNKD) said yesterday it had finalised the Phase III study of AFREZZA (insulin human [rDNA origin]) inhalation powder, its rapid-acting mealtime insulin therapy administered using the company's inhaler, in Type 2 diabetes patients.

The company added that it expects to unveil data from the study later during the summer. AFREZZA is being developed for the treatment of adult patients with Type 1 or Type 2 diabetes for the control of hyperglycemia.

The clinical trial, dubbed Study 175, evaluated AFREZZA using the next-generation inhaler in patients with Type 2 diabetes whose disease is inadequately controlled on metformin with or without a second or third oral medication. After a run-in period during which the subjects remained on their oral medication, 353 patients were randomised to additional treatment with AFREZZA or to Technosphere inhalation powder (placebo). The study also had a titration period, followed by a 12-week evaluation period to assess HbA1c levels.